137 related articles for article (PubMed ID: 29757301)
1. The content validity of the PSS in patients with plaque psoriasis.
Rentz AM; Skalicky AM; Burslem K; Becker K; Kaschinski D; Esser D; Revicki DA
J Patient Rep Outcomes; 2017; 1(1):4. PubMed ID: 29757301
[TBL] [Abstract][Full Text] [Related]
2. Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP).
Burden AD; Mrowietz U; Skalicky AM; Rentz AM; Esser D; Gloede T; Thoma C; Menter A
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1367-1381. PubMed ID: 35590037
[TBL] [Abstract][Full Text] [Related]
3. The experience of pain and redness in patients with moderate to severe plaque psoriasis.
Martin ML; Gordon K; Pinto L; Bushnell DM; Chau D; Viswanathan HN
J Dermatolog Treat; 2015 Oct; 26(5):401-5. PubMed ID: 25822169
[TBL] [Abstract][Full Text] [Related]
4. Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses.
Armstrong AW; Edson-Heredia E; Naegeli AN; Burge R; Poon JL; Anatchkova M; Sun L; Zhu B; Wyrwich KW
J Dermatolog Treat; 2020 Aug; 31(5):452-459. PubMed ID: 31157576
[No Abstract] [Full Text] [Related]
5. Validation of the PROFAD-SSI-SF in Patients with Primary Sjögren's Syndrome with Organ Involvement: Results of Qualitative Interviews and Psychometric Analyses.
Raymond K; Maher S; Saucier CD; O'Connor M; Yarlas A; Kosinski M; Chen WH; Gairy K
Rheumatol Ther; 2023 Feb; 10(1):95-115. PubMed ID: 36227531
[TBL] [Abstract][Full Text] [Related]
6. Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity.
Martin ML; McCarrier KP; Chiou CF; Gordon K; Kimball AB; Van Voorhees AS; Gottlieb AB; Huang X; Globe D; Chau D; Viswanathan HN; Kricorian G
J Dermatolog Treat; 2013 Aug; 24(4):255-60. PubMed ID: 23249143
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis.
Gottlieb AB; Ciaravino V; Cioffi C; Peterson L; Warren RB
Dermatol Ther (Heidelb); 2020 Dec; 10(6):1255-1272. PubMed ID: 32844372
[TBL] [Abstract][Full Text] [Related]
9. Reliability, validity, and the ability to detect change of the Psoriasis Symptom Scale (PSS) in patients with plaque psoriasis.
Rentz AM; Skalicky AM; Esser D; Zema C; Becker K; Bodhani A; Revicki DA
J Dermatolog Treat; 2020 Aug; 31(5):460-469. PubMed ID: 32045314
[No Abstract] [Full Text] [Related]
10. The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument.
Lebwohl M; Swensen AR; Nyirady J; Kim E; Gwaltney CJ; Strober BE
Int J Dermatol; 2014 Jun; 53(6):714-22. PubMed ID: 23557000
[TBL] [Abstract][Full Text] [Related]
11. Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(27):1-66. PubMed ID: 23074532
[TBL] [Abstract][Full Text] [Related]
12. Assessing asthma symptoms in children: qualitative research supporting the development of the Pediatric Asthma Diary-Child (PAD-C) and Pediatric Asthma Diary-Observer (PAD-O).
Bradley H; Trennery C; Jones AM; Lydon A; White F; Williams-Hall R; Arbuckle R; Tomaszewski E; Shih VH; Haughney J; Eisen A; Winders T; Coons SJ; Eremenco S;
J Patient Rep Outcomes; 2023 Oct; 7(1):104. PubMed ID: 37863864
[TBL] [Abstract][Full Text] [Related]
13. The experience of itch in children with psoriasis: A qualitative exploration of the Itch Numeric Rating Scale.
Mannix S; Edson-Heredia E; Paller AS; Yosipovitch G; Burge R; Kleinman L
Pediatr Dermatol; 2021 Mar; 38(2):405-412. PubMed ID: 33336430
[TBL] [Abstract][Full Text] [Related]
14. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
Augustin M; Lambert J; Zema C; Thompson EHZ; Yang M; Wu EQ; Garcia-Horton V; Geng Z; Valdes JM; Joshi A; Gordon KB
JAMA Dermatol; 2020 Dec; 156(12):1344-1353. PubMed ID: 33052382
[TBL] [Abstract][Full Text] [Related]
15. The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS).
Gottlieb AB; Kirby B; Ryan C; Naegeli AN; Burge R; Potts Bleakman A; Anatchkova MD; Yosipovitch G
Dermatol Ther (Heidelb); 2018 Mar; 8(1):45-56. PubMed ID: 29204893
[TBL] [Abstract][Full Text] [Related]
16. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups.
Globe D; Bayliss MS; Harrison DJ
Health Qual Life Outcomes; 2009 Jul; 7():62. PubMed ID: 19580674
[TBL] [Abstract][Full Text] [Related]
17. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity.
Bushnell DM; Martin ML; McCarrier K; Gordon K; Chiou CF; Huang X; Ortmeier B; Kricorian G
J Dermatolog Treat; 2013 Oct; 24(5):356-60. PubMed ID: 23092173
[TBL] [Abstract][Full Text] [Related]
18. The Severity of Chronic Cough Diary (SCCD): development and content validation of a novel patient-reported outcome instrument for evaluating the symptom experience of chronic cough.
de la Orden Abad M; Haberland C; Karn H; Skalicky A; Hareendran A
J Patient Rep Outcomes; 2023 Jul; 7(1):65. PubMed ID: 37428359
[TBL] [Abstract][Full Text] [Related]
19. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis.
Naegeli AN; Flood E; Tucker J; Devlen J; Edson-Heredia E
Int J Dermatol; 2015 Jun; 54(6):715-22. PubMed ID: 25515935
[TBL] [Abstract][Full Text] [Related]
20. Psychometric evaluation of the Symptoms of Infection with Coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial.
Chan EKH; Williams V; Romano C; Fehnel S; Slagle AF; Stoddard J; Sadoff J; Mayorga M; Lewis S; Yarr S; Ma J; Liu Y; Katz EG; McNulty P; van Dromme I; McQuarrie K
J Patient Rep Outcomes; 2023 May; 7(1):45. PubMed ID: 37195456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
